Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
Tonix Pharmaceuticals presented preclinical data for its immuno-oncology candidates TNX-1700 and TNX-4700 at the AACR Annual Meeting. TNX-1700 reversed aging-associated gastric inflammation and attenuated tumor progression in preclinical models, showing linear pharmacokinetics.
Key figures
- Drug Name
- TNX-1700 (TFF2-albumin fusion protein), TNX-4700 (human anti-BTLA monoclonal antibody)
- Phase Of Trial
- preclinical
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.